Hallmarks, Avoiding detection
Bruce Stillman, Ph.D. is president and chief executive officer of Cold Spring Harbor Laboratory, explains that there are two adaptive immune responses, and those immune responses adapt to changes in cells in our body whether they be by infection or other.
Cancer cells are often different in shape and size to normal cells, and they no longer respond to signals that control normal cellular functions. Our body's immune response is constantly surveilling for these emerging pre-cancers or pre-tumor cells. Successful cancers have to avoid detection long enough to grow into a tumor. Bruce Stillman, Ph.D., Cold Spring Harbor Laboratory: â€œThere are two what are called adaptive immune responses. And those immune responses adapt to changes in cells in our body whether they be by infection or other changes, perhaps such as cancer. That two arms of the adaptive immune response, one arm is making antibodies produced by B cells. And these antibodies bind and direct the elimination of those cells. The other part of the immune response is the T cell immune response where T cells actually kill cells that are changed in our body. There is constant surveillance of the cells in our body so that emerging pre- cancers or pre-tumor cells would be eliminated by the immune response.â€ Bruce Stillman, Ph.D. is president and chief executive officer of Cold Spring Harbor Laboratory. He is interested in understanding the mechanism and control of DNA replication in higher cells. Working in baker's yeast, he has identified DNA sequences and proteins that interact to initiatiate chromosome duplication. â€œA very exciting area of immunology is what is called adjuvant therapy. And this is where you stimulate the body's immune system with agents that activate the immune system and make them hypersensitive to these foreign cells in our body such as cancer cells. And there are a number of clinical trials going on now where the immune system is being enhanced by these kinds of adjuvant or stimulant therapies, and there has been some success although I think there is still a lot of research in this area to do.â€
cold spring harbor laboratory, bruce stillman, adaptive immune response, cancer cells, b cells, tumor cells, t cells, hallmarks, antibodies, t cell, one arm, immune responses, response one, cellular functions
- ID: 949
- Source: DNALC.IC
Bruce Stillman, Ph.D. is president and chief executive officer of Cold Spring Harbor Laboratory, discusses an area of immunology called adjuvant therapy, and how it is used to stimulate the body's immune system with agents that activate the immune system.
Bruce Stillman, Ph.D., president of Cold Spring Harbor Laboratory, explains that genomic instability is a characteristic of cancer cells.
Bruce Stillman, Ph.D., president of Cold Spring Harbor Laboratory discusses that you need to acquire multiple changes in genes estimated to be about 5-7 genes perhaps on average, to get a full-blown cancer.
In this section pharmacogenetics is discussed and how people can have very different responses to the same drug and treatment.
Nobel Prize week kicked-off today with the announcement of the Prize in Physiology or Medicine. Elizabeth Blackburn, Carol Greider, and Jack Szostak will share the award for discovering telomeres and telomerase. Dr. Bruce Stillman, President of Cold Sprin
Research continues to show that stem cells could be harnessed for therapeutic purposes.
In this section, hear what experts have to say about drugs that disrupt the function of receptors on a cell's surface.
The mosquito, Anopheles gambiae, has become an important model organism for the study of insect – parasite interactions and innate immune responses.
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.
Scott Lowe's research has shown how the regulation of the cell cycle affect cancer.